Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00079404 · ClinicalTrials.gov registry record · Phase 1
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase 1 study of Secondary Acute Myeloid Leukemia and Unspecified Childhood Solid Tumor, Protocol Specific, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT00079404: Completed Phase 1 study of Secondary Acute Myeloid Leukemia and Unspecified Childhood Solid Tumor, Protocol Specific, sponsored by National Cancer Institute (NCI).
NCT00079404 is a Phase 1 study of Secondary Acute Myeloid Leukemia and Unspecified Childhood Solid Tumor, Protocol Specific that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 36 participants, below the 58-participant average among 19 other Secondary Acute Myeloid Leukemia trials with a reported enrollment target (38% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00079404, a Phase 1 study of Secondary Acute Myeloid Leukemia and Unspecified Childhood Solid Tumor, Protocol Specific, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial is studying the side effects and best dose of 17-N-allylamino-17-demethoxygeldanamycin in treating young patients with relapsed or refractory solid tumors or leukemia. Drugs used in chemotherapy, such as 17-N-allylamino-17-demethoxygeldanamycin, work in different ways to stop cancer cells from dividing so they stop growing or die.
Conditions Studied
Interventions
- DRUG tanespimycin
Study Locations (1)
California
- COG Phase I Consortium - Arcadia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2004-03 |
| Phase | Phase 1 |
What the finished NCT00079404 record still lists
NCT00079404 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 58-participant average among 19 other Secondary Acute Myeloid Leukemia trials with a reported enrollment target (38% lower).
The record links to 5 conditions, with Secondary Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which tanespimycin is the first listed.
NCT00079404 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00079404 about?
NCT00079404 is a clinical study titled "17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia". This phase I trial is studying the side effects and best dose of 17-N-allylamino-17-demethoxygeldanamycin in treating young patients with relapsed or refractory solid tumors or leukemia. Drugs used in chemotherapy, such as 17-N-allylamino-17-demethoxygeldanamycin, work in different ways to stop canc...
What is the current status of trial NCT00079404?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2004-03.
What conditions does trial NCT00079404 study?
This clinical trial studies the following conditions: Secondary Acute Myeloid Leukemia, Unspecified Childhood Solid Tumor, Protocol Specific, Recurrent Childhood Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Recurrent Childhood Acute Myeloid Leukemia.
What interventions are being tested in trial NCT00079404?
The interventions under investigation include: tanespimycin (DRUG).
Who is sponsoring clinical trial NCT00079404?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00079404 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Secondary Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00079404's enrollment target sits among peer trials
36 12th of 19 higher than 8 of 19 other Secondary Acute Myeloid Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Secondary Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia
ACTIVE NOT RECRUITING · Phase 1
-
Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
ACTIVE NOT RECRUITING · Phase 1
-
Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia
ACTIVE NOT RECRUITING · Phase 1
-
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
ACTIVE NOT RECRUITING · Phase 1
-
90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia